Member Info for B2HS2L

Yes Van, - me too.
However, I can't reconcile the spelling out of a long term plan identifying revenue stream diversification, if a M&A event has not happened first.
The presentation of the above plan would be only half a plan, if the M&A event happened shortly afterwards.
For me M&A first, then the presentation of the whole long term plan.

M&A event scheduled for H1 2021 last I heard, and times almost up.
I prey we have not been paying Anthony Dyer to keep changing his mind about acquisition(s) for the last five months.

03.08.2020 - Rishi Sunak visits IT-IS prior to Takeover by Novacyt in October.

https://www.rishisunak.com/news/rishi-visits-technological-frontline-battle-against-covid-19

"The 20-employee company on the Stokesley Business Park has been working flat out since the start of the pandemic to meet unprecedented demand for its machines which it exports all over the world

It has doubled production capacity to produce 300 machines a month."

IMO the quote 'working flat out' was symptomatic of the reason GM acted and bought the company.

1 To ensure supply, and also ensure IT-IS orders were priority one.

2 Because GM knew that to meet future NCYT sales requirements, IT-IS would have to be manufacturing many times more units, in only a few short months time.

A bit like Lord Beaverbrook galvanising the manufacture of Spitfires before the Battle of Britain.

I can see the launch of Versalab portable spawning many new one man band businesses, both in UK and potentially abroad, once foreign health ministries learn that using a PCR instrument doesn't need a lab.
They just need to ask DHSC.

After news of the New Variant Assessment program, - more info on intentions for UK NHS and worldwide sampling and tracking with WHO.
NCYT's fast development of assays for new variants can ensure we are first to market an assay for a new variant.

++++

27.01.2021 - UK to share genomics expertise to identify COVID-19 variants
https://www.healthcareitnews.com/news/emea/uk-share-genomics-expertise-identify-covid-19-variants

The New Variant Assessment Platform will enable scientists and governments across the globe to sequence the full genetic code of COVID-19 in Britain’s genomics laboratories. This is intended to uncover new variants of the virus earlier and to help identify their individual mutations. The platform will also offer expert advice and support including training and resources to foreign countries, enabling optimised responses, both medically and politically.
++++

21.05.2021 - UK launches implementation plan for genomic healthcare system
The plan focuses on expanding the diversity and reach of genomics in the UK as well as improving patient diagnosis, treatment and sickness prevention.
https://www.healthcareitnews.com/news/emea/uk-launches-implementation-plan-genomic-healthcare-system

The plan outlines 27 commitments to further genomics in the UK, with 5 key goals:

A partnership between Genomics England and NHS England/Improvement to enable faster and more comprehensive genomic testing of cancer
Whole genome sequencing for patients with rare diseases
Ensure diverse datasets through bespoke screening programmes so that everyone in the UK can benefit from genomic databases
The advancement of Our Future Health research programme, supported by £79 million from UKRI
Develop global standards and policies for sharing genomic health data securely
Genomics England projects that support the implementation of the Genome UK strategy will receive £17 million from the government, it was announced in April. This will be used in part to increase data from ethnic minorities in particular genomic cohorts, which could enhance diagnosis and treatment of those in the BAME community.

++++

24.05.2021 - UK launches plan for ‘Global Pandemic Radar’
The network of surveillance hubs will identify and track new COVID variants and emerging diseases.
https://www.healthcareitnews.com/news/emea/uk-launches-plan-global-pandemic-radar

The UK is working with the World Health Organisation (WHO) to launch a ‘global pandemic radar’ to identify emerging COVID-19 variants and track new diseases around the world.
Prime minister Boris Johnson announced the plans on Friday (21 May), ahead of the Global Health Summit hosted by Italy and the European Union (EU).
The radar is expected to be fully up and running with a network of surveillance hubs before the end of 2021, with the aim of significantly improving global health security going into next year.
WHO will lead an implementation group, supported by global health charity the Wellcome

Hi K,
There will be a certain amount of investors who sold up and leave it too late to re-invest.
When news hits and with 71 Mil shares in issue, demand for shares will exceed supply, and I believe that to be an understatement. They just won't be getting back in with sufficient shares IMO.

JC5523 -
Page 5 of contract:

3 months Initial service and recalibration

6 months Full diagnostic and recalibration

12 months Full diagnostic and recalibration

Any failure by the Authority to arrange the servicing of the Instruments in
accordance with the above frequency (subject to a 2 month grace period) shall
invalidate the warranty provided in Clause 12 of Schedule 1 (Key Provisions) in
relation to the Instruments and the Supplier shall be under no further obligation to
maintain or repair the Instruments concerned.
(b) Field Service and Support (available in mainland UK only): where the Authority
elects to purchase this service, the Supplier shall ensure that, in addition to the
routine maintenance provided above, the Supplier shall either repair or replace a
defective Instrument within 24 hours of the defect being reported to the Supplier.

Training commitments also listed on this page.

Soder -
Just thinking out loud.

The second DHSC contract - Sept 28th 2020, phase 1:
Supply of
* q16 instruments
* q32 instruments
* exsig COVID-19 Direct kits
* genesig SARS-CoV-2 Winterplex kits.

Few posters have seen that there would have been minimum order levels for Winterplex.
Winterplex hasn't been mentioned in this dispute by GM, but it remains the case that even minimum order levels would leave DHSC overstocked, as Winterplex was hardly used in 2021 H1. (Not good with a product with a short shelf life - [6months?]).
DHSC might have made decisions about Winterplex deliveries that would give rise to contractual dispute.

Fits the scenario you describe Soder.

Had you thought that PROmate was supplied outside of the contract, because the contract was not functioning properly, and one way of getting paid was CoD.
Fanciful I know, but with a customer you suspect is going to take a lot of product rapidly, you absolutely need to know your getting paid on time.

....not to mention the odd shorter sizzling alamo...

manchego -
Should this dispute go to court, making everything about the dispute publicly available beforehand is not likely to assist the prosecution of Novacyt's case against DHSC.

It is a bit like your car insurance company saying that in the event of a road accident, don't admit liability. - if you did it would make it very hard to prove the other party is at fault if the insurers think that all other things considered, you would have a strong case.

If DHSC takes Novacyt to court, Novacyt making everything about the dispute publicly available beforehand could give another reason for DHSC grievance.

22 years later, a lot of 1998 Amazon share holders didn't see the ATH, - they were dead.
Just saying..:-)

Cummings says that the herd immunity approach is all over many meeting documents / presentations / graphs, - so how difficult is that going to be to locate copies of those documents?
Is he saying that because he has copies - affirmative.
Is herd immunity in the meeting minutes - ask Dominic.

We just need to know whether Dominic was in the same meetings as Jenny to know who has a bad memory.
That was the question Andrew Marr needed to ask.

Whatnonewsyet:
Eric Feigl-Ding on the same subject:
https://twitter.com/DrEricDing/status/1396397770924232704

However, - "It is now ~50% of all cases in England," isn't correct.
IMO he means Bolton and Bedford.

bights? - bites?
Tangling with Nick Plummer will show DHSC has bitten off much more than is chewable.
Hope they choke.

3)RNS unnecessary. Another one engineered to presures/p down.
+++

IMO the first RNS should have stated that Q4 2020 AND Q1 2021 figures could require review.

I believe Q4 2020 only was discussed because management was thinking that by now the dispute would have been resolved. This is a good sign because if correct, then management thought due process was likely to end the dispute in a timely fashion.

Clearly we are still in dispute, so management now required on 21st May to issue second RNS saying Q1 2021 will also need review, thus giving shorters and adverse market sentiment two bights of the cherry.
Own goal? - yes, but only because management thought dispute would be over by now.

He previewed his guests at 8:30 Breakfast TV, and said there was some good news, - lets hope the source is Jenny Harries!

Andrew will be interviewing Dr Jenny Harries, Chief Executive of UK Health Security Agency (UKHSA),

The UK Health Security Agency (UKHSA) is responsible for planning, preventing and
responding to external health threats, and providing intellectual, scientific and operational
leadership at national and local levels, as well as on the global stage. Through this, UKHSA
intends to ensure the nation can respond quickly and at greater scale to deal with pandemics
and future threats.

100:1 Novacyt gets mentioned
50:1 SNPsig gets mentioned.

VanV, -
With this level of embedding within UK Govnt agencies and WHO, and CE approval for instruments and Assays, and UK Govnt (Foreign office involvement) behind development of NVAP, there is only one way sales of SNPsig assays is going.
Perhaps UK govnt or WHO might later on supply these assays and company expertise to the least prosperous nations.
Future preparedness for other illnesses that become Pandemics is also part of the agenda.

Graham Mullis on Genetic Surveillance - 24.03.2021 RNS - Launch of VariPLEX CE-Mark test

"With VariPLEX™, we are offering an affordable, scalable and time efficient alternative to next generation sequencing which allows for reliable testing of key variants in a single test. By providing an on-site solution which reads out in less than two hours, we are ensuring that it is possible to track variants and the infections they cause on a global scale."

++++

Let the real journey begin - to infinity and beyond!!!

VanV - "Pages 26/27 - Conclusion: THIS is no small task!"

Standby for a bigger budget for UKHSA, - I agree the task is huge.

Establishing the NVAP support is critical to get countries with few or no genomic sequence facilities, (or trained epidemiologists), to get assistance with building facilities capable of contributing to a world genomic sequencing picture.

It looks as though Novacyt's instruments and open platform assays, combined with the fast development of new assays with which to identify recently identified mutations, are ideally placed to export to those countries that apply for assistance.

ie from the NVAP announcement (found at the foot of this post), applications via:
1 Countries can access support via a dedicated email address: nvap@phe.gov.uk
2 Hubs are being selected through joint work between the Foreign, Commonwealth and Development Office (FCDO), the Department of Health and Social Care (DHSC) and PHE, aligned with WHO assessment of global sequencing capacity.

Rapid support by a deployed team of experts may also be provided if needed.

The more applicants, the more the NCYT equipment and assays will become the default standard way of performing Genomic Sequencing, as competitor assays and equipment take much longer than the Primerdesign 2 to 3 hrs for assays to provide a test result, and the assistance identified here is available from no other source worldwide.
NVAP is committed to making data available globally through GIS-AID (database). This will allow it to inform UK risk assessment and pandemic control strategies globally.

++++

I don't see how the DHSC relationship can be harmed significantly over the second contract, if we are a central part of Public Health England and UK Health Security Agency plans for NVAP?

++++
https://www.gov.uk/guidance/new-variant-assessment-programme?utm_medium=email&utm_campaign=govuk-notifications&utm_source=91cff3a8-66dc-4857-89d0-85be91dc181f&utm_content=immediately

Apologies, missed another link out: -

Also referenced within the article at the 'document' hotlink, gives access to a SAGE document:

21.05.2021 - Setting up medium-and long-term vaccine strain selection and immunity management for SARS-CoV-2
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/988226/S1226_Setting_up_medium-_and_long-term_vaccine_strain_selection_and_immunity_management_for_SARS-CoV-2__1_.pdf

+++

30 pages :( but some of it essential reading for where Genomic Surveillance will go from here on.
Found pages 26/27 of interest.